INCONVENIENT HERITAGE AND PLACES OF POWER: THE INSTITUTION’S DNA. THE EXPERIENCE OF THE LVIV ACADEMIC PUPPET THEATRE
Proscenium · 2026 · 264 (75) · 109-117
DOI: 10.30970/prc.75.109-117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proscenium, 2026. Verfasst von Uliana MOROZ.
Abstract (Originalsprache)
The article identifies seven ideological mindsets (tentatively termed “specters of communism”) – ingrained at the time of the Lviv Academic Puppet Theater’s founding in 1945–that currently hinder reform. In contrast, the author proposes seven strategies and concepts (“places of power”) that, despite all challenges, serve as vital pillars and deserve to become established traditions today. The article analyzes the repertory and management models shaped under the totalitarian system, specifically examining the phenomenon of the “actor-performer,” the cultivation of fear, and the normalization of institutional violence. Particular attention is paid to analyzing the markers of propaganda and deconstructing dramatic texts–using the works of Yevgeny Schwartz as a case study – as vehicles for totalitarian patterns. The study outlines the processes of theatrical transformation since 2017 and proposes value-based “antidotes” to the institution’s Soviet DNA: dignity, creative freedom, solidarity, and a culture of dialogue.
Zitieren
APA
MOROZ, U. (2026). INCONVENIENT HERITAGE AND PLACES OF POWER: THE INSTITUTION’S DNA. THE EXPERIENCE OF THE LVIV ACADEMIC PUPPET THEATRE. Proscenium, 264(75), 109-117. https://doi.org/10.30970/prc.75.109-117
Vancouver
MOROZ U. INCONVENIENT HERITAGE AND PLACES OF POWER: THE INSTITUTION’S DNA. THE EXPERIENCE OF THE LVIV ACADEMIC PUPPET THEATRE. Proscenium. 2026;264(75):109-117. doi:10.30970/prc.75.109-117
BibTeX
@article{MOROZ2026,
author = {MOROZ, Uliana},
title = {INCONVENIENT HERITAGE AND PLACES OF POWER: THE INSTITUTION’S DNA. THE EXPERIENCE OF THE LVIV ACADEMIC PUPPET THEATRE},
journal = {Proscenium},
year = {2026},
volume = {264},
number = {75},
pages = {109--117},
doi = {10.30970/prc.75.109-117}
}
EUVIMED